Analyst Price Targets — NEUP
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 5, 2025 12:43 pm | — | H.C. Wainwright | $7.00 | $4.27 | TheFly | Neuphoria Therapeutics price target lowered to $7 from $21 at H.C. Wainwright |
Latest News for NEUP
Immunic (NASDAQ: IMUX - Get Free Report) and Neuphoria Therapeutics (NASDAQ: NEUP - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership. Profitability This table compares Immunic and Neuphoria Therapeutics'
Prenetics Global (NASDAQ: PRE - Get Free Report) and Neuphoria Therapeutics (NASDAQ: NEUP - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends. Institutional and Insider Ownership 25.0% of Prenetics
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NEUP.
U.S. House Trading
No House trades found for NEUP.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.